Search research articles
Contact Us
Filters
Showing results (311-320 of 323) with videos related to
Page
of 33
Sort By:
Blood Advances
|
March 15, 2022
High frequency of central nervous system involvement in transformed Waldenström macroglobulinemia
Eric Durot, Lukshe Kanagaratnam, Saurabh Zanwar, et al.
Seminars in Hematology
|
April 26, 2023
Report of consensus panel 1 from the 11<sup>th</sup> International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients
Christian Buske, Jorge J Castillo, Jithma Prasad Abeykoon, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 12, 2017
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
Shaji K Kumar, Natalie S Callander, Melissa Alsina, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
November 11, 2015
Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology
Kenneth C Anderson, Melissa Alsina, Djordje Atanackovic, et al.
Blood Advances
|
January 7, 2026
POD24 is a Novel Determinant of Prognosis in Patients with Waldenström Macroglobulinemia
Saurabh Zanwar, Jithma P Abeykoon, Shirley D'Sa, et al.
Blood Advances
|
June 5, 2025
Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia
Andrew R Branagan, Clifton Mo, Matthew Lei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 21, 2023
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study
Meletios A Dimopoulos, Stephen Opat, Shirley D'Sa, et al.
Blood
|
February 11, 2026
Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenström macroglobulinemia
Hao Sun, Romanos Sklavenitis Pistofidis, Shirong Liu, et al.
Blood Advances
|
February 5, 2024
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia
Constantine S Tam, Stephen Opat, Shirley D'Sa, et al.
Frontiers in Immunology
|
February 5, 2025
A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings
Steven P Treon, Camille N Kotton, David J Park, et al.
Page
of 33
Search research articles
Search
Showing results (311-320 of 323) with videos related to
Sort By:
Page
of 33
Blood Advances
|
March 15, 2022
High frequency of central nervous system involvement in transformed Waldenström macroglobulinemia
Eric Durot, Lukshe Kanagaratnam, Saurabh Zanwar, et al.
Seminars in Hematology
|
April 26, 2023
Report of consensus panel 1 from the 11<sup>th</sup> International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients
Christian Buske, Jorge J Castillo, Jithma Prasad Abeykoon, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 12, 2017
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
Shaji K Kumar, Natalie S Callander, Melissa Alsina, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
November 11, 2015
Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology
Kenneth C Anderson, Melissa Alsina, Djordje Atanackovic, et al.
Blood Advances
|
January 7, 2026
POD24 is a Novel Determinant of Prognosis in Patients with Waldenström Macroglobulinemia
Saurabh Zanwar, Jithma P Abeykoon, Shirley D'Sa, et al.
Blood Advances
|
June 5, 2025
Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia
Andrew R Branagan, Clifton Mo, Matthew Lei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 21, 2023
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study
Meletios A Dimopoulos, Stephen Opat, Shirley D'Sa, et al.
Blood
|
February 11, 2026
Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenström macroglobulinemia
Hao Sun, Romanos Sklavenitis Pistofidis, Shirong Liu, et al.
Blood Advances
|
February 5, 2024
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia
Constantine S Tam, Stephen Opat, Shirley D'Sa, et al.
Frontiers in Immunology
|
February 5, 2025
A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings
Steven P Treon, Camille N Kotton, David J Park, et al.
Page
of 33